Therapeutic Areas

Although in the last 10 years new innovative medicines have found their way into the treatment of clinically relevant conditions, many patients remain waiting to find an effective treatment. LxBio is committed to the improvement of the infection, neuroscience and ophthalmology therapeutic areas, through the development of solutions using different technological platforms.


The emergence of different species of pathogenic bacteria resistant to many currently available antimicrobial agents has become a critical problem in modern medicine, and the development of complementary antibacterial therapies has become one of the highest priorities in the scope of healthcare associated infections.

It has been well established that bacteriophage therapy is an innovative treatment for different types of infections, specifically the ones caused by multidrug resistant bacteria, for which many times there are no therapeutic options. Indeed, therapy using lytic bacteriophages presents itself as an efficient antimicrobial therapy approach in selected clinical environments due to its specificity and efficiency in lysing pathogenic bacteria.


Neurodegenerative diseases exhibit a complex and multifactorial nature that affects millions of individuals worldwide, constituting a challenge for the R&D of new and efficient drugs, and resulting in a large unmet need. Therefore, it becomes urgent to develop innovative and effective treatments.


Although clinically relevant progress has been made over the past decade in the treatment of eye conditions, there is still a lot to be done in the scope of the development of innovative and non-invasive treatments for patients with macular degeneration, diabetic retinopathy, among other eye diseases.

Monoclonal antibodies have come to revolutionize modern medicine in several therapeutic areas, including the treatment of several eye diseases. In fact, traditional antibodies are molecules with a big size and high molecular weight. Additionally, the local treatment of ophthalmologic diseases with antibodies has been done by intravitreal injections, such as the use of specific agents to treat macular degeneration disease.

The convenience of discovering new and safer effective antibodies, and a more practical administration route or delivery system remains an important issue.